Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer

Thiru Prasanna, Rachel Wong, Timothy Price, Jeremy Shapiro, Jeanne Tie, Hui Li Wong, Louise Nott, David Roder, Margaret Lee, Suzanne Kosmider, Azim Jalali, Matthew Burge, Robert Padbury, Guy Maddern, Scott Carruthers, James Moore, Michael Sorich, Christos S. Karapetis, Peter Gibbs, Desmond Yip

Research output: Contribution to journalReview articlepeer-review

12 Citations (Scopus)


Background: Resection of oligometastases improves survival in metastatic colorectal cancer (mCRC). It is unclear whether the benefit is consistent for BRAF V600E mutant (MT) and wild type (WT) mCRC. This retrospective analysis explores the influence of BRAF MT on survival after metastasectomy. Methods: Overall survival (OS) and recurrence-free survival (RFS) for BRAF MT and WT mCRC were evaluated. Survival was also analyzed in the cohort of BRAF MT with or without metastasectomy. Results: Five hundred and thirteen patients who had undergone metastasectomy were identified, 6% were BRAF-MT. Median age 63. Median OS in BRAF MT vs WT: 25.7 vs 48.5 months (hazard ratio [HR] 1.95; 1.18-3.22). However, difference was not significant in a multivariate model. Right primary tumor, intact primary, >1 metastatic site, non-R0 resection, peritoneal metastasis, and synchronous metastasis were independent predictors of worse OS. Among 364 patients with RFS data there was no difference between BRAF MT and WT (16 vs 19 months, p=0.09). In another cohort of 158 BRAF-MT patients, OS was significantly better after metastasectomy compared to “no metastasectomy” (HR 0.34; 0.18-0.65, P= 0.001). Proficient mismatch repair status showed a trend toward worse survival after metastasectomy in BRAF MT (HR 1.71, P = 0.08). Conclusion: OS did not differ after metastasectomy between BRAF MT and WT in a multivariate model. Median OS was >2 years in this study after metastasectomy among BRAFV600E MT patients suggesting a survival benefit of metastasectomy in this group where systemic therapeutic options are limited. Metastasectomy may be considered in carefully selected BRAF-MT patients.

Original languageEnglish
Article number100637
Number of pages9
JournalCurrent Problems in Cancer
Issue number1
Publication statusPublished - Feb 2021


  • BRAF V600E mutation
  • Metastasectomy
  • Metastatic colorectal cancer
  • Survival


Dive into the research topics of 'Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this